Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a biotechnology company focused on harnessing the genetics of the adaptive immune system for clinical use, has announced a new collaboration with Flatiron Health, a healthtech leader in oncology care. The two companies have integrated Adaptive’s clonoSEQ® test for measurable residual disease (MRD) monitoring into OncoEMR®, Flatiron’s cloud-based electronic medical record (EMR) system.
This integration streamlines MRD testing workflows for over 4,500 providers across more than 1,000 community-based cancer care sites in the U.S. Clinicians using OncoEMR can now order and review clonoSEQ test results directly within the EMR interface, offering faster access to critical disease monitoring data and helping inform personalized treatment decisions in real time.
Susan Bobulsky, Chief Commercial Officer for MRD at Adaptive Biotechnologies, emphasized the significance of the partnership: “This collaboration reflects our mutual commitment to supporting providers in community oncology settings, where most cancer patients in the U.S. are treated. By embedding clonoSEQ into OncoEMR, we’re ensuring clinicians can easily access MRD insights, enabling them to tailor treatment strategies with greater precision and ultimately improve patient outcomes.”
MRD refers to the small number of cancer cells that may persist after treatment and potentially lead to relapse. It is considered one of the most powerful prognostic indicators in blood cancers. Regular MRD testing provides a personalized, dynamic view of a patient’s response to therapy and is increasingly being adopted as a standard component of modern cancer care.
Quincy Weatherspoon, VP & GM of Flatiron Point of Care Solutions, added, “We’re excited to include clonoSEQ as part of our Molecular Profiling Integration (MPI) platform within OncoEMR. This solution helps both providers and laboratories by enabling efficient, accurate data exchange, and keeping every stage of the testing process connected and transparent. clonoSEQ brings substantial value to blood cancer care, and we’re proud to partner with Adaptive to expand its reach in community oncology.”
Effective July 1, 2025, the integration is live for all OncoEMR MPI users. clonoSEQ will remain accessible through Adaptive’s diagnostic portal and through additional EMR integrations beyond the Flatiron network.